Seraxis Announces Publication of Preclinical Data for a Novel Islet Replacement Therapy and Clinical Candidate SR-02 for Insulin-Requiring Diabetes; Oral Presentation at IPITA
Manuscript describes the unique character of a pancreatic endocrine cell population derived from a non-pluripotent stem cell that closely resembles native islets in composition and...
Seraxis to Provide Oral Update on Its Pancreatic Organoid Candidate for Functional Cure of T1D at the 59th Annual Meeting of the EASD
Dr. William Rust will give an oral presentation on Seraxis’ proprietary technology for the production of therapeutic pancreatic organoids from pancreas-derived stem cells, as well...
Seraxis Presents Successful Results Using Synthetic Replacement Endocrine Clusters for Type 1 Diabetes at the 4th IPITA / HSCI / JDRF Summit
Seraxis Inc., a pre-clinical stage company with a best-in-class islet replacement therapy for insulin-dependent diabetes, today announced the presentation of results from an efficacy study...